文献速递消化道肿瘤放疗

帕尼单抗联合术前放疗治疗局部晚期RAS野生型直肠癌:NEORIT多中心探索性单臂2期研究结果

Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-28

该多中心探索性单臂2期研究纳入54例RAS野生型局部晚期(临床II或III期)直肠癌患者,距肛缘0–12 cm,采用帕尼单抗单药联合术前放疗,主要终点为病理完全缓解(pCR)。结果显示pCR率仅3.7%,未达到预设的pCR率以支持进一步临床试验,但毒性谱较可接受,≥3级非血液学毒性主要为皮肤毒性(24%)和腹泻(10%)。

要点

  • 帕尼单抗联合术前放疗的pCR率仅3.7%,未达预设阈值。
  • 65%患者出现原发肿瘤或淋巴结降期,无≥2级血液学毒性。
  • 常见≥3级非血液学毒性为皮肤毒性(24%)与腹泻(10%)。

核心结论

  • 帕尼单抗联合放疗作为局部晚期直肠癌新辅助治疗毒性可接受,但未达到预设pCR率,不足以支持进一步临床试验。

研究设计与样本

  • 多中心探索性单臂2期研究(NEORIT),纳入54例RAS野生型局部晚期(临床II或III期)直肠癌患者,肿瘤距肛缘0–12 cm,中位年龄58岁。
  • 干预为帕尼单抗单药联合术前放疗,主要终点为pCR,次要终点包括安全性、手术并发症、临床反应、肿瘤降期及Dworak肿瘤消退分级。

主要发现

  • 3.7%的患者达到pCR。
  • 65%的患者出现原发肿瘤或淋巴结降期。
  • 未观察到≥2级血液学毒性。
  • 最常见的≥3级非血液学毒性为皮肤毒性(24%)和腹泻(10%)。

关键数值与推荐

  • pCR率为3.7%,未达到预设的pCR率。
  • 原发肿瘤或淋巴结降期率为65%。
  • ≥3级皮肤毒性发生率为24%,≥3级腹泻发生率为10%。

临床怎么用

  • 结果提示帕尼单抗单药联合术前放疗不宜作为局部晚期RAS野生型直肠癌的常规新辅助方案推广。

局限性

  • 为单臂探索性2期研究,未设对照臂,样本量为54例,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal growth factor receptor inhibition and chemoradiation therapy, we conducted a phase 2 study using single-agent panitumumab in combination with radiation therapy in patients with RAS wild-type locally advanced rectal cancer. METHODS AND MATERIALS: Patients with RAS wild-type locally advanced (clinical stage II or III) rectal cancer localized 0 to 12 cm from the anus were eligible for study participation. The primary objective of the study was to determine pathologic complete response (pCR). Secondary objectives comprised assessing the safety, surgical morbidity, clinical response, tumor downstaging, and tumor regression grading according to Dworak. RESULTS: A total of 54 patients with a median age of 58 years were treated. In 3.7% of patients, pCR was achieved. Downstaging of the primary tumor or lymph nodes was seen in 65% of patients. No grade ≥2 hematologic toxicity was seen. The most common grade ≥3 nonhematologic toxicities were skin toxicity (24%) and diarrhea (10%). CONCLUSIONS: Panitumumab in combination with radiation therapy as neoadjuvant treatment for locally advanced rectal cancer showed a favorable toxicity profile but failed to meet the predefined pCR rate to justify further clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Merx K, Martens UM, Kripp M, et al. Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT. Int J Radiat Oncol Biol Phys. 2017. PMID: 28870789. doi:10.1016/j.ijrobp.2017.06.2460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。